CBER

Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Prasad’s replacement is “likely to fall further along the ‘right-to-try’ arm of the MAHA-RFK policy side,” Leerink analyst Mani Foroohar said.
Angus Liu Jul 31, 2025 9:10am
target reach ladder climb meet win beat competition
Favicon Fierce Pharma

FDA taps new CDER chief as acting CBER head after Prasad exit

Jul 30, 2025 1:10pm
FDA
Favicon Fierce Pharma

FDA investigates 2 deaths after Sarepta Duchenne gene therapy

Jun 25, 2025 10:26am
FDA
Favicon Fierce Pharma

FDA's acting CDER head heads for the exit: report

Jun 23, 2025 1:48pm
parachute sun

BMS banks on Wall Street vet for strategy— Chutes & Ladders

Jun 20, 2025 8:30am
Cartoon of humanoid robot sitting at computer working

FDA hopes AI can deliver 'rapid or instant' reviews

Jun 11, 2025 12:45pm